Pro-Oncogenic Role of a Mitochondrial Lipid Kinase in CLL

线粒体脂质激酶在 CLL 中的促癌作用

基本信息

项目摘要

PROJECT SUMMARY Chronic lymphocytic leukemia (CLL) is an adult B-cell malignancy accounting for about a third of leukemia diagnoses in the US. While B-cell receptor (BCR)-signal-inhibitors are changing the management of CLL, these are not curative and resistance can develop; often leading to more aggressive disease. Given this, understanding the molecular events driving CLL oncogenesis and therapeutic resistance warrants in-depth investigation. CLL is a disease characterized by extensive clonal proliferation and accumulation of malignant B lymphocytes in the blood, bone marrow, spleen, and lymph nodes. CLL shows remarkable clinical heterogeneity, with some patients pursuing an indolent course, while others progress rapidly and require early treatment. In the past 10 years, new insights into the biological function of a mitochondrial lipid kinase, acylglycerol kinase (AGK), as a key oncogene that is highly expressed in a range of tumor types, including prostate cancer, breast cancer, cervical squamous cell carcinoma, and esophageal squamous cell carcinoma have been established. Most recently, we found aberrantly high level expression of AGK in CLL cells from ~60% of pre-therapy CLL patients. However, the mechanism of aberrant upregulation of AGK in CLL cells, and its precise functional contributions to CLL cell biology and pathogenesis remain unknown. Interestingly, we detected nuclear/cytoplasmic localization of AGK in some CLL clones suggesting its multi-functional role. In line with this, we found that siRNA- mediated depletion of AGK in primary CLL cells resulted in marked inhibition of constitutively active multiple signal mediators including AKT, Erk1/2, LYN, BTK (downstream targets of BCR signal) and JAK2. Our preliminary findings also indicate that MYC may regulate AGK expression in CLL cells. Our combined data suggest that aberrant expression of AGK may potentiate cell survival signals including BCR and JAK2 in some CLL clones resulting in resistance to BCR-targeted therapies. Therefore, the central hypothesis of this application is that aberrant expression of AGK in some CLL clones represents highly aggressive CLL with shorter time to therapy. We also postulate that AGK upregulation potentiates CLL cell survival signals and resistance to BCR- targeted agents. We propose – Aim 1: Evaluate if aberrant expression of AGK in CLL cells drives disease progression; Aim 2: Define the mechanism of AGK upregulation and its role in CLL cell biology, signaling and potential as a therapeutic target. The proposed in-depth studies will assess if “high AGK” level in CLL cells serves as a risk factor for CLL progression, time to therapy and treatment outcome; define the impact of AGK aberrant expression on CLL cell survival and resistance to current BCR-targeted therapies. Thus, the proposed studies have enormous potential to establish a new prognostic parameter and therapeutic avenue via targeting AGK in CLL cells with or without the current BCR-targeted therapy, ibrutinib.
项目总结 慢性淋巴细胞性白血病(CLL)是一种成人B细胞恶性肿瘤,约占白血病的三分之一 在美国的诊断。虽然B细胞受体(BCR)信号抑制剂正在改变CLL的管理,但这些 不能治愈,会产生抗药性;通常会导致更具侵袭性的疾病。有鉴于此,理解 驱动CLL肿瘤发生和治疗耐药的分子事件值得深入研究。 CLL是一种以广泛的克隆性增殖和恶性B淋巴细胞聚集为特征的疾病 在血液、骨髓、脾和淋巴结中。CLL表现出显著的临床异质性,有一些 患者追求缓慢的疗程,而其他患者进展迅速,需要早期治疗。在过去10年中 多年来,人们对线粒体脂肪激酶--甘油酰基激酶(AGK)的生物学功能有了新的认识。 在一系列肿瘤类型中高表达的关键癌基因,包括前列腺癌、乳腺癌、 宫颈鳞癌和食道鳞状细胞癌已经成立。多数 最近,我们发现约60%的治疗前CLL患者的CLL细胞中AGK的表达异常高。 然而,在CLL细胞中AGK异常上调的机制及其确切的功能贡献 对CLL的细胞生物学和发病机制尚不清楚。有趣的是,我们检测到了细胞核/细胞质 AGK在一些CLL克隆中的定位表明其具有多功能作用。与此相一致,我们发现siRNA- 在原代CLL细胞中介导的AGK耗竭导致对构成活性多倍体的显著抑制 信号介体包括AKT、ERK1/2、LYN、BTK(BCR信号的下游靶标)和JAK2。我们的 初步研究结果还表明,MYC可能调节CLL细胞AGK的表达。我们的综合数据 提示AGK的异常表达可能增强了包括bcr和JAK2在内的一些细胞生存信号。 CLL克隆导致对bcr靶向治疗的抵抗。因此,这一应用程序的中心假设 AGK在某些CLL克隆中的异常表达代表了高度侵袭性的CLL,其发病时间较短 心理治疗。我们还假设AGK上调增强了CLL细胞的生存信号和对bcr-1的耐药性。 目标特工。我们建议-目标1:评估在CLL细胞中AGK的异常表达是否会导致疾病 目的2:明确AGK上调的机制及其在CLL细胞生物学、信号转导和免疫调节中的作用 作为治疗靶点的潜力。拟议的深入研究将评估CLL细胞中“高AGK”水平是否起作用 作为慢性淋巴细胞白血病进展、治疗时间和治疗结果的危险因素;确定AGK异常的影响 CLL细胞存活和对当前bcr靶向治疗的耐药性的表达。因此,拟议的研究 具有通过靶向AGK建立新的预后参数和治疗途径的巨大潜力 使用或不使用当前bcr靶向治疗ibrutinib的CLL细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Asish Kumar Ghosh其他文献

Impact of Annular Solar Eclipse on the Trace Gases and Dynamics of the Lower and Middle Atmosphere: Results Inferred From an Integrated Campaign “Suryagrahan‐2019”
日环食对中低层大气的微量气体和动力学的影响:从综合活动“Suryagrahan-2019”推断的结果
  • DOI:
    10.1029/2023ea003044
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    S. Das;K. Kishore Kumar;K. Subrahmanyam;M. Venkat Ratnam;K. V. Suneeth;S. Sunilkumar;P. R. Sinha;Asish Kumar Ghosh;Subrata Kumar Das;Sunil Sonwabne;U. MuraliKrishna;Y. Kolte;M. Naja;S. Abhilash;K. Satheesan;V. Rakesh;P. Mahesh;N. Koushik;P. R. Satheesh Chandran;I. Girach;K. V. S. Namboodiri;G. Pandithurai;N. KiranKumar
  • 通讯作者:
    N. KiranKumar
Location-specific weather predictions for Sriharikota (13.72°N, 80.22°E) through numerical atmospheric models during satellite launch campaigns
  • DOI:
    10.1007/s11069-011-9942-1
  • 发表时间:
    2011-08-28
  • 期刊:
  • 影响因子:
    3.700
  • 作者:
    D. Bala Subrahamanyam;Radhika Ramachandran;S. Indira Rani;S. Sijikumar;T. J. Anurose;Asish Kumar Ghosh
  • 通讯作者:
    Asish Kumar Ghosh

Asish Kumar Ghosh的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Asish Kumar Ghosh', 18)}}的其他基金

Study Pro-Oncogenic Role of BCL6 in CLL Tumorigenesis
研究 BCL6 在 CLL 肿瘤发生中的促癌作用
  • 批准号:
    10512700
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
Study Pro-Oncogenic Role of BCL6 in CLL Tumorigenesis
研究 BCL6 在 CLL 肿瘤发生中的促癌作用
  • 批准号:
    10661814
  • 财政年份:
    2022
  • 资助金额:
    $ 16.95万
  • 项目类别:
Microvesicle Dynamics in B-Cell Chronic Lymphocytic Leukemia Tumor Microenvironme
B 细胞慢性淋巴细胞白血病肿瘤微环境中的微泡动态
  • 批准号:
    9064090
  • 财政年份:
    2013
  • 资助金额:
    $ 16.95万
  • 项目类别:
Microvesicle Dynamics in B-Cell Chronic Lymphocytic Leukemia Tumor Microenvironme
B 细胞慢性淋巴细胞白血病肿瘤微环境中的微泡动力学
  • 批准号:
    9295841
  • 财政年份:
    2013
  • 资助金额:
    $ 16.95万
  • 项目类别:
Microvesicle Dynamics in B-Cell Chronic Lymphocytic Leukemia Tumor Microenvironme
B 细胞慢性淋巴细胞白血病肿瘤微环境中的微泡动力学
  • 批准号:
    8703043
  • 财政年份:
    2013
  • 资助金额:
    $ 16.95万
  • 项目类别:
Microvesicle Dynamics in B-Cell Chronic Lymphocytic Leukemia Tumor Microenvironme
B 细胞慢性淋巴细胞白血病肿瘤微环境中的微泡动力学
  • 批准号:
    8574032
  • 财政年份:
    2013
  • 资助金额:
    $ 16.95万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
  • 批准号:
    2230829
  • 财政年份:
    2023
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 16.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了